ReviewCurrent neuropharmacology2025
Synaptic Interactions Between Serotonergic and Dopaminergic Systems in Parkinson's Disease.
Review in Current neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neuromodulatory Gating of Synaptic Plasticity: Mechanisms, Motivation, and Clinical Dysfunction Across Scales.Synapse (New York, N.Y.) · 2026Review
- Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since both serotonergic and dopaminergic afferents densely innervate many parts of the central nervous system, intact crosstalk between serotonin (5-HT) and dopamine (DA) transmission is essential for regulating synaptic plasticity in the striatum (STR), prefrontal cortex (PFC), and hippocampus (HPC). Experimental models have provided strong evidence of a synergistic action of DA and 5-HT convergent release in PFC, HPC, and STR to modulate motor control, learning, and memory processes. In this review, we will discuss the mechanisms underlying the actions of agonists and antagonists of 5-HT and DA receptors on striatal synaptic plasticity in physiological conditions and Parkinson's disease (PD), a movement disorder in which an imbalance of these two neurotransmitter systems has been hypothesized. This review will also discuss the interactions between 5-HT and DA in PFC and HPC, with particular regard to the influence of this crosstalk on synaptic plasticity and learning. Finally, we will provide an overview of how stimulation or inhibition of DA and 5- HT receptors affects these neurotransmitter expression levels in the three brain regions of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.